Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV
2022; Lippincott Williams & Wilkins; Volume: 36; Issue: 5 Linguagem: Inglês
10.1097/qad.0000000000003161
ISSN1473-5571
AutoresManuel González de Aledo, Angelina Cañizares, Pilar Vázquez‐Rodríguez, Ángeles Castro, L. Moldes, Soledad López, E Míguez, Germán Bou, Álvaro Mena,
Tópico(s)Animal Virus Infections Studies
ResumoTo evaluate the safety and the serological response after two doses of mRNA-based SARS-CoV-2 vaccination in people with HIV (PWH).Participants were evaluated 4 weeks after the second dose of mRNA-1273 or BNT162b2 vaccine. Tolerability was evaluated with a specific adverse event questionnaire. Patient's sera were analysed using LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin).One-hundred PWH were included, 75% of them men, with a mean age of 44 ± 11 years old, all receiving antiretroviral treatment and mostly with controlled viral loads (98% with HIV RNA 200 CD4+/μl. All patients seroconverted after vaccination (antibody concentration ≥33.8 binding antibody units [BAU]/ml). Only 3% of the patients had a low antibody concentration ( 2080 BAU/ml). Fifty-six patients had local or systemic symptoms, with mild arthromyalgia being the most common systemic symptom. No severe adverse events were reported.Vaccination with two doses of mRNA-1273 or BNT162b2 is well tolerated in PWH under effective antiretroviral treatment and it leads to a successful antibody response.
Referência(s)